H.R. 7085 · 118th Congress (2023–2025)
BIOSECURE Act
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
Specifically, the bill prohibits executive agencies from (1) procuring or obtaining any biotechnology equipment or service produced or provided by a biotechnology company of concern, or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.
A biotechnology company of concern includes BGI, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of such entities, and any entity that
- is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary;
- is involved in the manufacturing, distribution, provision, or procurement of a biotechnology equipment or service; and
- poses a risk to U.S. national security based on specified activities.
Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.
The Office of Management and Budget must develop and periodically update a list of the entities that constitute biotechnology companies of concern.
Show official title
To prohibit contracting with certain biotechnology providers, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is H.R. 7085’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Mike Gallagher (R-WI-8)
- Cosponsors
10 cosponsors
4 original · 6 later
4 R · 6 D
- Rep. Jake Auchincloss (D-MA-4)· Original · Jan 25, 2024
- Rep. Neal P. Dunn (R-FL-2)· Original · Jan 25, 2024
- Rep. Raja Krishnamoorthi (D-IL-8)· Original · Jan 25, 2024
- Rep. Seth Moulton (D-MA-6)· Original · Jan 25, 2024
- Rep. Donald G. Davis (D-NC-1)· Later · Feb 7, 2024
- Rep. Elise M. Stefanik (R-NY-21)· Later · Feb 7, 2024
- Rep. Brad R. Wenstrup (R-OH-2)· Later · Mar 19, 2024
- Rep. John R. Moolenaar (R-MI-2)· Later · Apr 5, 2024
- Rep. Josh Gottheimer (D-NJ-5)· Later · Apr 20, 2024
- Rep. Anna G. Eshoo (D-CA-16)· Later · May 1, 2024
- Policy area
- Government Operations and Politics
- Subjects
- Asia
- China
- Europe
- Health technology, devices, supplies
- Iran
- Middle East
- North Korea
- Public contracts and procurement
1 more
- Russia
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Oversight and Accountability.
Sources
- Congress.gov action
- House floor actions
Expired
Introduced → Referred to House Oversight and Accountability → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
BIOSECURE Act
Display title, Short title · Introduced in House
To prohibit contracting with certain biotechnology providers, and for other purposes.
Official title · Introduced in House